Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · IEX Real-Time Price · USD
13.00
+0.04 (0.31%)
At close: Apr 22, 2024, 4:00 PM
12.61
-0.39 (-3.00%)
After-hours: Apr 22, 2024, 4:19 PM EDT

Zentalis Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018
Revenue
000000.01
Gross Profit
000000.01
Selling, General & Admin
64.3554.5540.9433.898.464.88
Research & Development
235.16172.73175.684.938.3918.92
Operating Expenses
299.51227.29216.54118.7946.8523.8
Operating Income
-299.51-227.29-216.54-118.79-46.85-23.78
Other Expense / Income
-6.729.99-57.52-1.39-1.2-2.72
Pretax Income
-292.79-237.28-159.02-117.4-45.65-21.06
Income Tax
-0.6-0.47-0.30.440.020
Net Income
-292.19-236.81-158.73-117.84-45.66-21.07
Shares Outstanding (Basic)
6553432866
Shares Outstanding (Diluted)
6553432866
Shares Change
23.75%23.82%51.84%402.29%0.05%-
EPS (Basic)
-4.47-4.48-3.72-4.19--3.77
EPS (Diluted)
-4.47-4.48-3.72-4.19--3.77
Free Cash Flow
-208.41-166.3-160.2-87.58-39.5-24.48
Free Cash Flow Per Share
-3.19-3.15-3.75-3.12-7.06-4.38
Gross Margin
-----100.00%
Operating Margin
------169878.57%
Profit Margin
------150478.57%
Free Cash Flow Margin
------174842.86%
EBITDA
-291.4-235.85-158.48-117.24-45.54-21.01
EBITDA Margin
------150085.71%
Depreciation & Amortization
1.391.430.540.160.110.05
EBIT
-292.79-237.28-159.02-117.4-45.65-21.06
EBIT Margin
------150450.00%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).